Minenkova et al., 2021 - Google Patents
Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19Minenkova et al., 2021
View PDF- Document ID
- 10885508158157377063
- Author
- Minenkova O
- Santapaola D
- Milazzo F
- Anastasi A
- Battistuzzi G
- Chiapparino C
- Rosi A
- Gritti G
- Borleri G
- Rambaldi A
- Dental C
- Viollet C
- Pagano B
- Salvini L
- Marra E
- Luberto L
- Rossi A
- Riccio A
- Pich E
- Santoro M
- De Santis R
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
As of June 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global emergency and effective therapeutic interventions for the treatment and prevention of coronavirus disease 2019 (COVID-19) are urgently needed. SARS-CoV-2-neutralizing …
- 241001678559 COVID-19 virus 0 title abstract description 51
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gorman et al. | Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination | |
| Nambulli et al. | Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses | |
| Li et al. | Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection | |
| Swanson et al. | A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain | |
| Corti et al. | Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | |
| Planas et al. | Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization | |
| He et al. | Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice | |
| Zohar et al. | Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates | |
| He et al. | Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus | |
| He et al. | Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones | |
| Wu et al. | Influenza A surface glycosylation and vaccine design | |
| Respaud et al. | Nebulization as a delivery method for mAbs in respiratory diseases | |
| Wonderlich et al. | Widespread virus replication in alveoli drives acute respiratory distress syndrome in aerosolized H5N1 influenza infection of macaques | |
| Tan et al. | Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin | |
| Milner et al. | Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infection | |
| Paik et al. | Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity | |
| Simhadri et al. | A human anti-M2 antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine secretion by resting and cytokine-preactivated natural killer (NK) cells | |
| Chen et al. | Prospects of neutralizing nanobodies against SARS-CoV-2 | |
| George et al. | Neutrophils and influenza: a thin line between helpful and harmful | |
| Miyauchi et al. | Influenza virus infection expands the breadth of antibody responses through IL-4 signalling in B cells | |
| Nachbagauer et al. | Broadly reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice against highly pathogenic H5N1 challenge | |
| EP4161647A1 (en) | Therapeutic antibodies with neutralizing activity against sars-cov-2 glycoprotein s | |
| Urano et al. | An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models | |
| Amanat et al. | Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein | |
| Nakayama et al. | SARS-CoV-2 Related antibody-dependent enhancement phenomena in vitro and in vivo |